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Objectives: Classification of breast cancer patients into different risk classes is
very important in clinical applications. It is estimated that the advent of high-
dimensional gene expression data could improve patient classification. In this
study, a new method for transforming the high-dimensional gene expression data
in a low-dimensional space based on wavelet transform (WT) is presented.
Methods: The proposed method was applied to three publicly available micro-
array data sets. After dimensionality reduction using supervised wavelet, a
predictive support vector machine (SVM) model was built upon the reduced
dimensional space. In addition, the proposed method was compared with the
supervised principal component analysis (PCA).
Results: The performance of supervised wavelet and supervised PCA based on
selected genes were better than the signature genes identified in the other
studies. Furthermore, the supervised wavelet method generally performed better
than the supervised PCA for predicting the 5-year survival status of patients with
breast cancer based on microarray data. In addition, the proposed method had a
relatively acceptable performance compared with the other studies.
Conclusion: The results suggest the possibility of developing a new tool using
wavelets for the dimension reduction of microarray data sets in the classification
framework.ted under the terms of the Creative Commons Attribution Non-Commercial License (http://
) which permits unrestricted non-commercial use, distribution, and reproduction in any
operly cited.
ase Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
Supervised wavelet for predicting breast cancer metastasis 3251. Introduction
Metastatic breast cancer is a stage of breast cancer
where the disease has spread to distant organs or tissues.
Treatments against metastasis exist, but usually further
treatments after surgery can have serious side effects
and involve high medical costs [1]. An important task to
optimize the adjuvant chemotherapy of metastasis
related to breast cancer is to diagnose the risk of
metastasis accurately [2e4].
Classification of cancer patients into different risk
classes is very important in clinical applications.
Traditional methods for patient classification were
mainly based on a series of clinical and histological
features [3]. It is estimated that the advent of high-
dimensional gene expression data could improve pa-
tient classification [5]. Gene expression profiles of breast
tumor samples could be used to predict relapse and
metastatic patterns in breast cancer patients that could
be potential candidate targets for new treatments [4]. It
is reasonable to assume that any difference between the
two tumors should be represented by some difference in
gene expression. However, in microarray studies, the
number of samples is relatively small compared to the
number of genes per sample. Furthermore, from the
biological aspect, only a small portion of genes have
predicted the power for phenotypes. If all or most of the
genes are considered in the predictive model, they can
induce substantial noise and thereby lead to poor pre-
dictive performance [6]. Thus, in order to obtain good
classification accuracy, a crucial step towards the
application of microarray data is the dimensional
reduction from the gene expression profiles. In recent
years, both feature selection and feature extraction
methods have been widely used for classifying gene
expression data [7]. Bair and Tibshirani [8] and Bair
et al. [9] explored the use of supervised principal
component analysis (PCA), which is similar to con-
ventional PCA except that it uses a subset of the pre-
dictors selected based on their association with the
outcome. Wavelet-based methods have also been used
to solve the dimension reduction problem. The primary
intuition for applying wavelets in the case of gene
expression is that genes are often coexpressed in groups.
Therefore, it would be useful to treat the group as a
single variable, akin to the motivation behind methods
such as PCA [10]. One-dimensional discrete wavelet
transform (DWT) is frequently used for feature extrac-
tion in the analysis of high-dimensional biomedical data
[11]. Studies showed that this method has an acceptable
performance in the field of feature extraction in the
classification framework [11e15].
The current study aimed to introduce a dimension
reduction strategy for transforming the high-dimensional
gene expression data in a low-dimensional space based
on wavelet transform (WT) in order to predict metastasisof breast cancer. Accordingly, a predictive support vector
machine (SVM) model was built upon the reduced
dimensional space. Then, the proposed novel supervised
wavelet method of feature extraction was compared with
the supervised PCA.2. Materials and methods
The proposed method was applied to three publicly
available microarray data sets related to breast cancer.
2.1. Data
2.1.1. Breast cancer data from van’t Veer
(NKI_97)
The first data set is reported by van’t Veer et al [2] and
referred to as NKI_97. The original van’t Veer data
consists of gene expression profiles and clinical infor-
mation for 97 samples of primary breast cancer tumors,
and each case is described by the expression levels of
24,481 genes. Fifty-one patients remained free from
metastasis for at least 5 years and were metastasis-
negative, and 46 cancer patients developed metastasis
within 5 years and were metastasis-positive. All patients
were<55 years old and were lymph node-negative. They
had no tumor cells in local lymph nodes [2]. The data used
in this study is a filtered version of the van’t Veer data
including gene expression values of 4948 genes in 97
tumor samples [2]. The data are publicly available at the
“cancer data” R package (http://www.bioconductor.org/
packages/release/data/experiment/html/cancerdata.html).
2.1.2. Breast cancer data from van de Vijver
(NKI_295)
The second data set is reported by van de Vijver et al
[4] and referred to as NKI_295. The data set provides
the gene information for 295 primary breast cancer pa-
tients, of which 234 patients were new and the
remaining 61 patients were involved in the first data set.
Of the total 295 patients, 194 patients were metastasis-
negative and 101 patients were metastasis-positive. Of
the 234 new patients, 164 patients were metastasis-
negative and 70 patients were metastasis-positive. Of
the 61 patients involved in the first data set, 30 were
metastasis-negative and 31 patients were metastasis-
positive. The data is a filtered version of the van de
Vijver data including gene expression values of 4948
genes in 295 tumor samples [4]. The data are publicly
available at the “cancer data” R package.
2.1.3. Breast cancer data from the Wang study
(VDX_286)
The last data set, reported by Wang et al [16] and
referred to as VDX_286, contains 286 lymph node-
negative breast cancer patients who had not received
any adjuvant systemic treatment [16]. Among them, 106
326 M. Farhadian, et alpatients had distant metastasis within 5 years of follow
up and were considered as metastatic patients, while the
rest were considered as nonmetastatic patients. A set of
22,283 genes is available for this data set. The data are
publicly available at the “breast cancer VDX” R
package.2.2. Wavelet Transform
A wavelet is a “small wave”, which has its energy
concentrated in time. In signal processing, a trans-
formation technique is used to transfer data in another
domain where hidden information can be extracted.
Wavelets have a nice feature of local description and
separation of signal characteristics, and provide a tool
for the analysis of transient or time-varying signals [11].
A wavelet is a set of orthonormal basis functions
generated from dilation and translation of a single
scaling function or father wavelet (4) and a mother
wavelet (j).
WTs are classified into two different categories: the
continuous WT and the DWT. The DWT is a linear
operation that operates on a data vector, transforming it
into a wavelet coefficient. The idea underlying DWT is
to express any function f ðtÞ˛L2ðRÞ in terms of o¨ (t) and
ø (t) as follows:
f ðtÞZ
X
k
c0ðkÞ4ðt kÞ þ
X
k
X
jZ1
djðkÞ2
j
2 j

2jt k
Z
X
k
cj0ðkÞ2
j0
2 4

2j0tkþX
k
X
jZj0
djðkÞ2
j
2 j

2jtk
ð1Þ
where 4ðtÞ, jðtÞ, c0; and dj represent the scaling func-
tion, mother wavelet function, scaling coefficients
(approximation coefficients) at scale zero, and detail
coefficients at scale j, respectively. The variable k is the
translation coefficient for the localization of gene
expression data. The scales denote the different (low to
high) scale bands. The variable symbol j0 is the scale
(level) number selected [10].
One-dimensional DWT decomposes a signal as a sum
of wavelets at different time shifts and scales (fre-
quencies) using DWT. For this purpose, the signal is
passed through a series of high-pass and low-pass filters
in order to analyze low as well as high frequencies in the
signal as follows:
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where hðm 2kÞ and h1ðm 2kÞ are the low-pass filters
and high-pass filters, respectively.At each level, the high-pass filter produces detail
coefficients (wavelet coefficients) d1, while the low-pass
filter associated with the scaling function produces
approximation coefficients (scaling coefficients) c1.
Subsequently, the approximation coefficients c1 are split
into two parts by using the same algorithm and are
replaced by c2 and d2, and so on. This decomposition
process is repeated until the required level is reached.
The coefficient vectors are produced by down sampling
and are only half the length of the signal or the coeffi-
cient vector at the previous level [12].
The main advantage of the WT is that each basis
function is localized jointly in both the time and fre-
quency domains. From a viewpoint of time-frequency,
the approximation coefficients correspond to the larger-
scale low-frequency components, and the detail co-
efficients correspond to the small-scale high-frequency
components. Generally, the former can be used to
approximate the original signal, and the latter represents
some local details of the original signal [14,15].
There are different families of wavelets: symlets,
coiflets, Daubechies, and biorthogonal wavelets. They
vary in the various basic properties of wavelets, such as
compactness. Haar wavelets, belonging to Daubechies
wavelet family, are the most commonly used wavelets in
database literature because they are easy to comprehend
and fast to be computed.
2.3. Q-value
It is usual to simultaneously test many hundreds or
thousands of genes in microarray studies to determine
which are differentially expressed. Each of these tests
will produce a p value. One main challenge in those
studies is to find suitable multiple testing procedures that
provide an accurate control of the error rates. Whereas
the p value is a measure of significance in terms of the
false positive rate, the q value is an approach used to
measure statistical significance based on the concept of
the false discovery rate. Similar to the p value, the q
value gives each feature its own individual measure of
significance [17].
2.4. Supervised WT
Firstly, any patients who remain free from metastasis
for at least 5 years are placed into Class 1, otherwise into
Class 2. The proposed DWT-based feature selection
method consists of the following steps: (1) A t test is
taken as the measure to identify differently expressed
genes and a list of q values is derived. All the genes are
ranked according to their corresponding q value and the
required numbers of genes are selected from the list; and
(2) in each step the top number of genes based on the q
value are picked out. Then, this reduced set of genes is
modeled by the one-dimensional DWT using Haar
mother wavelet and finally, the wavelet approximation
coefficients in the first and second levels of decompo-
sition are used in the SVM model, respectively.
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Bair and Tibshirani [8] and Bair et al [9] proposed
supervised principal components regression. This pro-
cedure first picks out a subset of the gene expressions
that correlates with response by using univariate selec-
tion, and then applies PCA to this subset. In our anal-
ysis, we pick out the top number of genes based on q
values. We then apply PCA to this subset of genes, and
in each step include the top numbers of principal com-
ponents into a SVM model. The top numbers of prin-
cipal components that will be comprised of at least 75%
of the total variance are included in the SVM model.2.6. SVM
The SVM model proposed by Vapnik [18] is a su-
pervised learning method that is widely used in micro-
array data classification. Unlike many modeling
techniques which aim to minimize the objective func-
tion (such as mean square error) for all instances, SVM
attempts to find the hyperplanes that produce the largest
separation between the decision function values for the
instances located on the borderline between the two
classes. The optimally identified hyperplane in the
feature space corresponds to a nonlinear decision
boundary in the input space. The SVM takes a set of
input data with corresponding class labels and predicts a
new input which belongs to the classes.
In the binary classification mode, given a training set
of instance-label pairs (xi; yi) iZ1; 2;.;N ; where
xi˛Rp and y˛f1;þ1g SVM can be regarded as the
solution of the following quadratic optimization
problem:
min
W;b;g
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where the training data are mapped to a higher dimen-
sional space by the function 4 and C is a user-defined
penalty parameter on the training error that controls
the trade-off between classification errors and the
complexity of the model. By solving the optimization
problem (1) by finding the parameters w and b for a
given training set, a decision hyperplane over an n-
dimensional input space that produces the maximal
margin in the space is designed. Thus, the decision
function can be formulated as follows:
f ðxÞZsignWT4ðxÞ þ b ð5Þ
SVM can derive the optimal hyperplane for non-
linearly separated data by mapping the impute data into
the n-dimensional space using kernel function
[Kðxi; xjÞZ4ðxiÞT4ðxjÞ]. There are four basic kernels:
linear, polynomial, radial basic function, and sigmoid
[18,19].In this study, the goal of SVM modeling was to
classify patients who had a high risk of breast cancer
recurrence. The predictive performance of the SVM-
classifier was reported based on sensitivity, specificity,
accuracy, and the area under the receiver operating
characteristic curve (AUC). These criteria are defined as
follows: (TP Z true positive; TN Z true negative;
FN Z false negative; and FP Z false positive):
Accuracy: ACC Z TPþTN
TPþFPþTNþFN
Sensitivity: SN Z TP
TPþFN
Specificity: SP Z FP
FPþTN
The method is implemented using MATLAB r2012a
software (MATLAB Release 2012a, the MathWorks,
Inc., Natick, Massachusetts, United States) and R sta-
tistical package (e1071, q value).
2.7. Cross data set comparison
To avoid over fitting and to provide a realistic eval-
uation, the cross data method was used. In this method,
features obtained from one data set were used to
construct classifiers for the other data set. In this regard,
common patients in the NKI_295 and NKI_97 data were
removed and the remaining data (NKI_234) were used
as a test data set. This method was implemented using
genes selected from NKI_234 breast cancer data as input
in the supervised wavelet method in the NKI_61 data.3. Results
The t test statistics were used to identify discrimi-
native genes in each data set. After selecting the top
ranked genes based on q values, one-dimensional WT in
the first and second levels was applied to these pre-
selected genes. SVMs with three types of kernelsd-
linear, sigmoid, and radial, were used based on wavelet
approximation coefficients in the first and the second
levels of decomposition. For further assessment of the
reported subsets of 70 genes selected by van’t Veer et al
[2] (for NKI_97 and NKI_295) and 76 signature genes
selected by Wang et al [16] (for VDX_286), the su-
pervised wavelet method and supervised PCA were
applied. The predictive performance of SVM models
was tested by cross-validation, consisting of 10 times
10-folding experiments. The results of supervised
wavelet and supervised PCA for the three data sets are
shown in Tables 1e3, respectively.
In the NKI_97 data set, the results showed that the
SVM with radial kernels based on wavelet approxima-
tion coefficients in the first level extracted from 58
preselected genes had the best performance in terms of
the evaluation criteria with regard to accuracy (83.11) as
well as AUC (83.45). In addition, the SVM with radial
kernel based on the first supervised PCA computed
based on 84 preselected genes had the best performance
328 M. Farhadian, et alin terms of accuracy (79.22) as well as specificity
(83.25), sensitivity (75.22), and AUC (79.24). In both
methods (supervised wavelet and supervised PCA), the
classifier performance based on the 70 genes selected by
q values was better than the 70 gene signature from the
van’t Veer study (Table 1).
In the NKI_295 data set (Table 2), the results showed
that the SVM with radial kernels based on wavelet
approximation coefficients in the first level extracted
from 91 preselected genes had the best performance in
terms of the evaluation criteria, with the highest accu-
racy (75.37) as well as AUC (70.03). In addition, the
SVM with linear kernel based on the first supervised
PCA computed based on 91 preselected genes had the
best performance in terms of accuracy (73.03) as well as
AUC (66.63). In both methods (supervised wavelet and
supervised PCA), the classifier performance based onTable 1. Results for supervised wavelet and supervised principa
validation.
Method No. of preselected genes. Method
SVM (linear) 70 genes (van’t Veer) Wavelet (Db1
Wavelet (Db1
Supervised PC
SVM (radial) 70 genes (van’t Veer) Wavelet (Db1
Wavelet (Db1
Supervised PC
SVM (sigmoid) 70 genes (van’t Veer) Wavelet (Db1
Wavelet (Db1
Supervised PC
SVM (linear) 70 genes Wavelet (Db1
Wavelet (Db1
Supervised PC
SVM (radial) 70 genes Wavelet (Db1
Wavelet (Db1
Supervised PC
SVM (sigmoid) 70 genes Wavelet (Db1
Wavelet (Db1
Supervised PC
SVM (linear) q < 0.02 (84 genes) Wavelet (Db1
Wavelet (Db1
Supervised PC
SVM (radial) q < 0.02 (84 genes) Wavelet (Db1
Wavelet (Db1
Supervised PC
SVM (sigmoid) q < 0.02 (84 genes) Wavelet (Db1
Wavelet (Db1
Supervised PC
SVM (linear) q < 0.01 (58 genes) Wavelet (Db1
Wavelet (Db1
Supervised PC
SVM (radial) q < 0.01 (58 genes) Wavelet (Db1
Wavelet (Db1
Supervised PC
SVM (sigmoid) q < 0.01 (58 genes) Wavelet (Db1
Wavelet (Db1
Supervised PC
AUC Z area under the receiver operating characteristic curve; SVM Z suppthe 70 genes selected by q values was better than the 70
gene signature from the van’t Veer study.
In the VDX_286 data set (Table 3), the results showed
that the SVM with linear kernels based on wavelet
approximation coefficients in the second level extracted
from 67 preselected genes had the best performance with
the highest accuracy (79.21) as well as AUC (76.04). In
addition, the SVM with linear kernel based on the first
supervised PCA computed based on 67 preselected genes
had the best performance in terms of accuracy (76.00) as
well as AUC (74.71). In both methods (supervised
wavelet and supervised PCA), the classifier performance
based on the selected 76 genes using t statistics was better
than the 76 gene signature identified in the Wang study.
To evaluate the reproducibility of the proposed
method, a cross data-set comparison was also per-
formed. As shown in Table 4, the results confirmed thatl component analysis (PCA): NKI_97, 10 times 10-fold cross-
Accuracy Sensitivity Specificity AUC
.1) 77.11 78.30 76.15 77.22
.2) 69.11 64.47 73.00 68.74
A 73.77 75.72 71.84 73.78
.1) 77.55 82.28 73.24 77.76
.2) 75.66 82.20 69.76 75.98
A 71.77 71.25 72.21 71.73
.1) 78.88 78.57 79.18 78.87
.2) 71.88 74.82 69.26 72.04
A 68.77 67.58 69.73 68.66
.1) 72.33 67.55 76.38 71.97
.2) 76.44 75.53 77.24 76.38
A 74.00 72.51 75.31 73.91
.1) 82.77 90.14 74.46 82.30
.2) 82.00 88.47 76.21 82.34
A 75.88 75.22 76.52 75.87
.1) 77.44 86.74 68.93 77.84
.2) 77.00 82.86 71.72 77.29
A 78.22 76.83 79.45 78.14
.1) 71.00 68.40 73.09 70.75
.2) 72.88 72.09 73.67 72.88
A 78.00 78.01 77.98 78.00
.1) 82.55 87.55 78.21 82.88
.2) 81.66 84.47 79.00 81.73
A 79.22 83.25 75.22 79.24
.1) 79.88 88.17 72.53 80.35
.2) 78.88 86.62 70.94 78.78
A 75.55 80.00 71.48 75.74
.1) 73.77 76.62 71.34 73.98
.2) 70.88 67.78 73.95 70.86
A 76.66 79.36 74.07 76.71
.1) 83.11 88.27 78.63 83.45
.2) 82.33 85.11 79.55 82.33
A 77.33 82.43 72.72 77.58
.1) 80.66 89.69 72.51 81.10
.2) 80.77 85.77 76.07 80.92
A 76.00 80.87 71.86 76.37
ort vector machine.
Table 2. Results for supervised wavelet and supervised principal component analysis (PCA): NKI_295, 10 times 10-fold
cross-validation.
Method No. of preselected genes Method Accuracy Sensitivity Specificity AUC
SVM (linear) 70 genes (van’t Veer) Wavelet (Db1.1) 65.10 38.32 77.82 58.07
Wavelet (Db1.2) 66.13 29.71 84.33 57.02
Supervised PCA 67.00 28.55 87.38 57.97
SVM (radial) 70 genes (van’t Veer) Wavelet (Db1.1) 70.96 32.82 90.37 61.59
Wavelet (Db1.2) 67.96 26.37 88.64 57.50
Supervised PCA 65.72 18.36 91.14 54.75
SVM (sigmoid) 70 genes (van’t Veer) Wavelet (Db1.1) 63.17 24.70 81.82 53.26
Wavelet (Db1.2) 64.55 19.25 88.10 53.67
Supervised PCA 66.27 23.73 89.04 56.39
SVM (linear) 70 genes Wavelet (Db1.1) 70.20 48.68 81.29 64.98
Wavelet (Db1.2) 72.65 53.08 82.52 67.80
Supervised PCA 69.37 45.83 81.71 63.77
SVM (radial) 70 genes Wavelet (Db1.1) 71.13 36.98 88.76 62.87
Wavelet (Db1.2) 70.06 39.92 86.22 63.07
Supervised PCA 70.10 34.41 89.37 61.89
SVM (sigmoid) 70 genes Wavelet (Db1.1) 65.79 43.03 77.08 60.06
Wavelet (Db1.2) 63.44 44.50 73.72 59.11
Supervised PCA 68.86 33.92 87.55 60.74
SVM (linear) q < 0.001 (56 genes) Wavelet (Db1.1) 69.68 48.65 80.87 64.76
Wavelet (Db1.2) 67.20 41.12 80.87 60.99
Supervised PCA 71.68 46.81 84.56 65.68
SVM (radial) q < 0.001 (56 genes) Wavelet (Db1.1) 70.37 33.90 89.40 61.65
Wavelet (Db1.2) 65.72 28.30 86.48 57.39
Supervised PCA 70.82 40.54 86.62 63.58
SVM (sigmoid) q < 0.001 (56 genes) Wavelet (Db1.1) 65.79 44.68 76.53 60.60
Wavelet (Db1.2) 66.37 41.38 79.49 60.43
Supervised PCA 71.10 45.46 84.21 64.83
SVM (linear) q < 0.002 (91 genes) Wavelet (Db1.1) 72.37 46.50 86.00 66.25
Wavelet (Db1.2) 70.43 80.97 57.00 67.24
Supervised PCA 73.03 46.51 86.76 66.63
SVM (radial) q < 0.002 (91 genes) Wavelet (Db1.1) 75.37 52.85 87.21 70.03
Wavelet (Db1.2) 74.58 49.18 86.48 67.83
Supervised PCA 71.06 39.56 88.05 63.81
SVM (sigmoid) q < 0.002 (91 genes) Wavelet (Db1.1) 72.44 42.36 88.01 65.19
Wavelet (Db1.2) 74.34 47.21 88.38 67.80
Supervised PCA 69.10 49.47 78.63 64.05
AUC Z area under the receiver operating characteristic curve; SVM Z support vector machine.
Supervised wavelet for predicting breast cancer metastasis 329the supervised wavelet method also had an acceptable
performance, although the improvements were not as
high as in the inner data set comparison. The results of
other studies based on the same data sets are shown in
Table 5. It can be seen that the proposed method had a
higher capability for the prediction of metastasis than
the other studies [20e29].4. Discussion
This study proposed a new method based on WT to
develop a novel predictive model for the prediction of
breast cancer metastasis. Furthermore, the performance
of this method was compared with supervised PCA.
The main purpose of the feature extraction method
using WT is that the approximation coefficients usuallycomprise the majority of the important information [11].
In addition, the powerful capability of the DWT to
compress the signal energy makes it a good candidate
for feature extraction applications. The DWT com-
presses most of the energy from the input signal and
concentrates it in a few high-magnitude coefficients in
the transformed matrix.
The wavelet feature extraction method does not
depend on the training data set to obtain the basis of
feature space compared to the PCA method. Therefore,
the wavelet feature extraction method dramatically re-
duces the computation load compared to PCA [11,12].
Considering the fact that most genes are irrelevant to
patients’ metastasis, we analyzed the reduced data set
given by selecting genes that were significantly related
to metastasis based on the t test statistics. If the WT is
performed directly by using all of the genes in a data set,
Table 3. Results for supervised wavelet and supervised principal component analysis (PCA): VDX_286, 10 times 10-fold
cross-validation.
Method No. of preselected genes Method Accuracy Sensitivity Specificity AUC
SVM (linear) 76 genes (Wang) Wavelet (Db1.1) 64.42 44.42 76.25 60.33
Wavelet (Db1.2) 66.39 44.86 79.13 61.99
Supervised PCA 68.17 39.13 85.82 62.47
SVM (radial) 76 genes (Wang) Wavelet (Db1.1) 63.89 35.74 79.77 57.75
Wavelet (Db1.2) 65.10 28.97 87.45 58.21
Supervised PCA 67.82 33.97 87.88 60.92
SVM (sigmoid) 76 genes (Wang) Wavelet (Db1.1) 66.92 45.49 79.66 62.58
Wavelet (Db1.2) 65.64 43.42 79.11 61.27
Supervised PCA 67.39 43.54 81.28 62.41
SVM (linear) 76 genes Wavelet (Db1.1) 75.17 61.97 83.02 72.50
Wavelet (Db1.2) 76.35 59.94 85.99 72.96
Supervised PCA 67.96 42.04 83.65 62.85
SVM (radial) 76 genes Wavelet (Db1.1) 76.07 60.80 84.86 72.83
Wavelet (Db1.2) 77.25 56.48 89.23 72.86
Supervised PCA 67.32 37.17 85.37 61.27
SVM (sigmoid) 76 genes Wavelet (Db1.1) 77.21 62.41 86.10 74.26
Wavelet (Db1.2) 71.57 61.79 77.34 69.56
Supervised PCA 68.10 42.85 82.77 62.81
SVM (linear) q < 0.04 (67 genes) Wavelet (Db1.1) 78.21 67.05 84.60 75.83
Wavelet (Db1.2) 79.21 64.46 87.61 76.04
Supervised PCA 76.00 68.76 80.66 74.71
SVM (radial) q < 0.04 (67 genes) Wavelet (Db1.1) 77.00 58.65 87.56 73.10
Wavelet (Db1.2) 75.17 54.41 88.33 71.37
Supervised PCA 75.00 60.97 83.68 72.33
SVM (sigmoid) q < 0.04 (67 genes) Wavelet (Db1.1) 77.03 65.75 83.54 74.65
Wavelet (Db1.2) 78.50 66.79 85.59 76.19
Supervised PCA 75.21 64.96 81.63 73.30
SVM (linear) q < 0.05 (86 genes) Wavelet (Db1.1) 77.00 67.04 83.02 75.03
Wavelet (Db1.2) 78.17 65.57 85.62 75.60
Supervised PCA 75.96 66.14 82.11 74.12
SVM (radial) q < 0.05 (86 genes) Wavelet (Db1.1) 75.96 55.15 88.20 71.68
Wavelet (Db1.2) 76.17 53.57 89.45 71.51
Supervised PCA 75.57 63.50 82.98 73.24
SVM (sigmoid) q < 0.05 (86 genes) Wavelet (Db1.1) 77.32 66.18 83.91 75.04
Wavelet (Db1.2) 74.67 59.40 83.36 71.38
Supervised PCA 74.28 65.61 79.19 72.40
AUC Z area under the receiver operating characteristic curve; SVM Z support vector machine.
330 M. Farhadian, et althere is no guarantee that the resulting wavelet co-
efficients will be related to metastasis. Thus, this study
introduced a supervised form of WT that can be
considered as a supervised wavelet. After extracting
supervised wavelet approximation coefficients using
discrete Haar WT, these coefficients had higher pre-
dictive performances than the first three principal com-
ponents. Therefore, our results suggested that the
wavelet coefficients are the efficient way to characterize
the features of high-dimensional microarray data.
Because the performance of the proposed supervised
wavelet method is likely to be improvable compared to
some other studies, we conclude that this method is
worth further investigation as a tool for cancer patient
classification based on gene expression data. For
example, to achieve optimal classification performance,a suitable combination of the classifier and the gene
selection method needs to be specifically selected for a
given data set.
Some studies reported misclassification rates that
were obtained by the application of their classifier to a
one splitting of the test and training set. For example,
van’t Veer et al [2] developed a 70-gene classifier pre-
dicting a distant metastasis of breast cancer. In the
training set, the classifier predicted the class of 65/78
cases correctly (i.e., with an accuracy of 83.3%, corre-
sponding to a weighted accuracy of 83.6%), whereas in
the test set it predicted the class of 17/19 cases correctly
(i.e., with an accuracy of 89.5%, corresponding to a
weighted accuracy of 88.7%). However, in the present
study, in order to avoid the over fitting problem, we
followed the 10 times 10-fold cross-validation for
Table 5. Previously published analyses for the breast cancer data.
No. of samples Feature selection Classifier Measure Validation method
Current study 97 Supervised wavelet SVM radial kernel Accuracy: 83.11 CV
Supervised PCA SVM radial kernel Accuracy: 79.22
295 Supervised wavelet SVM radial kernel Accuracy: 75.37
Supervised PCA SVM linear kernel Accuracy: 73.03
286 Supervised wavelet SVM linear kernel Accuracy: 79.21
Supervised PCA SVM linear kernel Accuracy: 76.00
Michiels et al
(2005) [20]
97 Correlation Nearest-centroid Accuracy: 68.00 CV
Peng (2005) [23] 97 Signal to noise ratio SVM Accuracy: 75.00 Leave-one-out CV
Signal to noise ratio Bagg & Boost SVM Accuracy: 77.00
Subsampling Ensemble SVM Accuracy: 81.00
Pochet et al
(2004) [24]
78þ19* None LS-SVM linear kernel Accuracy: 69.00 Leave-one-out CV
None SVM RBF kernel Accuracy: 69.00
None SVM linear kernel Accuracy: 52.00
Alexe et al
(2006) [22]
78þ19 Support set identified by
logical analysis of data
SVM linear kernel Accuracy: 77.00 CV
Artificial NN Accuracy: 79.00
Logistic regression Accuracy: 78.00
Nearest neighbors Accuracy: 76.00
Decision trees (C4.5) Accuracy: 67.00
Jahid et al
(2012) [26]
295 Steiner tree based method SVM Accuracy: 62.00 CV
286 Accuracy: 61.00
Chuang et al
(2007) [25]
295 Subnetwork marker SVM Accuracy: 72.00 CV
286 Accuracy: 62.00
van Vliet et al
(2012) [21]
295 Filtering approach (t test) Nearest mean
classifier
AUC: 73.80 CV
Dehnavi et al
(2013) [27]
286 Rough-set theory Neuro-fuzzy System Accuracy: 78.00 10-fold CV
Lee et al
(2011) [28]
286 Modules with condition
responsive correlations
Naı¨ve Bayesian
classifier
AUC: 0.62 Leave-one-out CV
Jahid et al
(2014) [29]
295 Patientepatient
co-expression networks
PC-classifier AUC: 0.78 Leave-one-out CV
Dagging AUC: 0.72
AdaBoost AUC: 0.66
286 PC-classifier AUC: 0.68
Dagging AUC: 0.61
AdaBoost AUC: 0.55
AUC Z area under the receiver operating characteristic curve; CV Z cross validation; PCA Z principal component analysis; RBF Z radial basic
function; SVM Z support vector machine.
Table 4. External validation for supervised wavelet: NKI_234_61, 10 times 10-fold cross-validation.
Method No. of preselected genes Wavelet Accuracy Sensitivity Specificity AUC
SVM (linear) 70 genes Db1. Level 1 67.83 75.63 59.15 67.39
Db1. Level 2 64.33 69.45 58.82 64.13
SVM (radial) 70 genes Db1. Level 1 64.50 72.47 54.94 63.71
Db1. Level 2 67.66 67.94 67.36 67.65
SVM (sigmoid) 70 genes Db1. Level 1 65.66 72.93 58.24 65.59
Db1. Level 2 62.16 56.06 68.47 62.27
SVM (linear) q < 0.00 (13 genes) Db1. Level 1 64.00 68.81 59.34 64.07
Db1. Level 2 61.50 53.96 69.82 61.89
SVM (radial) q < 0.003 (13 genes) Db1. Level 1 71.83 78.33 65.33 71.83
Db1. Level 2 69.00 70.16 67.86 69.01
SVM (sigmoid) q < 0.003 (13 genes) Db1. Level 1 70.66 65.06 76.73 70.90
Db1. Level 2 68.83 67.89 69.76 68.83
AUC Z area under the receiver operating characteristic curve; SVM Z support vector machine.
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332 M. Farhadian, et alevaluating the SVM classifier. The evaluation of the
classifier based on one test set is very impressed with the
data splitting process.
Future investigations can focus on different ways of
preselecting genes in the first stage of the proposed
method. For example, rather than ranking genes based
on their t test scores, one would use a different metric to
measure the association between a given gene and
metastasis occurrence. By contrast, another mother
wavelet and a different level of decomposition can be
studied. In this study, gene expression data were
employed as predictors. However, prediction perfor-
mance may be improved by adding other covariates such
as age, lymph node status, tumor size, and histological
grade. It is likely that the classification performances
could be improved with the use of some other classifiers.
This study confirmed that the SVM model based on
the supervised wavelet feature extraction method was
superior with regards to predictive performance than the
supervised PCA and some other studies. Gene expres-
sion profiling can help to distinguish between patients at
high risk and those at low risk for developing distant
metastases, therefore, this technology and other high-
throughput techniques are helping to alter our view of
breast cancer and provide us with new tools for mo-
lecular diagnoses. These results exhibit the possibility of
developing a new tool using wavelets for the dimension
reduction of microarray data sets in the classification
framework and therefore, the use of this method in
similar classification problems is recommended.Conflicts of interest
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